Matches in SemOpenAlex for { <https://semopenalex.org/work/W4313642045> ?p ?o ?g. }
Showing items 1 to 92 of
92
with 100 items per page.
- W4313642045 endingPage "S38" @default.
- W4313642045 startingPage "S37" @default.
- W4313642045 abstract "Objective To evaluate the safety and efficacy of efgartigimod in patients with generalized myasthenia gravis (MG) enrolled in the ADAPT+ long-term extension study. Background Treatment with efgartigimod, a human IgG1 antibody Fc-fragment that blocks neonatal Fc receptor, resulted in clinically meaningful improvement (CMI) in MG-specific outcome measures in the ADAPT phase 3 clinical trial. All patients who completed ADAPT were eligible to enroll in its ongoing open-label, 3-year extension study, ADAPT+. Design/Methods Efgartigimod (10 mg/kg IV) was administered in cycles of once-weekly infusions for 4 weeks, with subsequent cycles initiated based on clinical evaluation. Efficacy was assessed during each cycle utilizing Myasthenia Gravis Activities of Daily Living (MG-ADL) and Quantitative Myasthenia Gravis (QMG) scales. Results Ninety-one percent of ADAPT patients (151/167) entered ADAPT+. As of February 2021, 106 AChR-Ab+ and 33 AChR-Ab– patients had received at least 1 dose of open-label efgartigimod (including 66 ADAPT placebo [PBO] patients). The mean (SD) study duration was 363 (114) days, resulting in 138 patient-years of observation. Similar incidence rates per patient year (IR/PY) of serious adverse events were seen in ADAPT (efgartigimod: 0.11; placebo: 0.29) compared to ADAPT+ (0.25). Five deaths (acute myocardial infarction, COVID-19 pneumonia/septic shock, bacterial pneumonia/MG crisis, malignant lung neoplasm, and unknown [multiple cardiovascular risk factors identified on autopsy]) occurred; none were considered related to efgartigimod by the investigator. AEs were predominantly mild or moderate. CMI was observed in AChR-Ab+ patients during each cycle (up to 10 cycles) at magnitudes comparable to improvements observed at week 3 of cycle 1 (mean[SE] improvements: MG-ADL, –5.1[0.34]; QMG, –4.7[0.41]). Clinical improvements mirrored maximal reductions in total IgG and AChR-Abs across all cycles. Conclusions This analysis suggests the efficacy of long-term treatment with efgartigimod was consistent across multiple cycles. No new safety signals were identified, despite being conducted before vaccine availability during the COVID-19 pandemic." @default.
- W4313642045 created "2023-01-07" @default.
- W4313642045 creator A5008162199 @default.
- W4313642045 creator A5015168451 @default.
- W4313642045 creator A5029639314 @default.
- W4313642045 creator A5029827503 @default.
- W4313642045 creator A5031155343 @default.
- W4313642045 creator A5032850040 @default.
- W4313642045 creator A5046178114 @default.
- W4313642045 creator A5047572275 @default.
- W4313642045 creator A5048372627 @default.
- W4313642045 creator A5055953731 @default.
- W4313642045 creator A5059723595 @default.
- W4313642045 creator A5065638265 @default.
- W4313642045 creator A5070152512 @default.
- W4313642045 creator A5070602040 @default.
- W4313642045 creator A5077281690 @default.
- W4313642045 creator A5082026989 @default.
- W4313642045 creator A5082524383 @default.
- W4313642045 date "2022-12-05" @default.
- W4313642045 modified "2023-09-25" @default.
- W4313642045 title "Long-term Safety and Efficacy of Efgartigimod in Patients With Generalized Myasthenia Gravis: Interim Results of the ADAPT+ Study" @default.
- W4313642045 doi "https://doi.org/10.1212/01.wnl.0000903308.81107.e2" @default.
- W4313642045 hasPublicationYear "2022" @default.
- W4313642045 type Work @default.
- W4313642045 citedByCount "3" @default.
- W4313642045 countsByYear W43136420452023 @default.
- W4313642045 crossrefType "journal-article" @default.
- W4313642045 hasAuthorship W4313642045A5008162199 @default.
- W4313642045 hasAuthorship W4313642045A5015168451 @default.
- W4313642045 hasAuthorship W4313642045A5029639314 @default.
- W4313642045 hasAuthorship W4313642045A5029827503 @default.
- W4313642045 hasAuthorship W4313642045A5031155343 @default.
- W4313642045 hasAuthorship W4313642045A5032850040 @default.
- W4313642045 hasAuthorship W4313642045A5046178114 @default.
- W4313642045 hasAuthorship W4313642045A5047572275 @default.
- W4313642045 hasAuthorship W4313642045A5048372627 @default.
- W4313642045 hasAuthorship W4313642045A5055953731 @default.
- W4313642045 hasAuthorship W4313642045A5059723595 @default.
- W4313642045 hasAuthorship W4313642045A5065638265 @default.
- W4313642045 hasAuthorship W4313642045A5070152512 @default.
- W4313642045 hasAuthorship W4313642045A5070602040 @default.
- W4313642045 hasAuthorship W4313642045A5077281690 @default.
- W4313642045 hasAuthorship W4313642045A5082026989 @default.
- W4313642045 hasAuthorship W4313642045A5082524383 @default.
- W4313642045 hasBestOaLocation W43136420451 @default.
- W4313642045 hasConcept C120665830 @default.
- W4313642045 hasConcept C121332964 @default.
- W4313642045 hasConcept C126322002 @default.
- W4313642045 hasConcept C142724271 @default.
- W4313642045 hasConcept C197934379 @default.
- W4313642045 hasConcept C204787440 @default.
- W4313642045 hasConcept C27081682 @default.
- W4313642045 hasConcept C2777914695 @default.
- W4313642045 hasConcept C2778105408 @default.
- W4313642045 hasConcept C535046627 @default.
- W4313642045 hasConcept C61511704 @default.
- W4313642045 hasConcept C61943457 @default.
- W4313642045 hasConcept C71924100 @default.
- W4313642045 hasConceptScore W4313642045C120665830 @default.
- W4313642045 hasConceptScore W4313642045C121332964 @default.
- W4313642045 hasConceptScore W4313642045C126322002 @default.
- W4313642045 hasConceptScore W4313642045C142724271 @default.
- W4313642045 hasConceptScore W4313642045C197934379 @default.
- W4313642045 hasConceptScore W4313642045C204787440 @default.
- W4313642045 hasConceptScore W4313642045C27081682 @default.
- W4313642045 hasConceptScore W4313642045C2777914695 @default.
- W4313642045 hasConceptScore W4313642045C2778105408 @default.
- W4313642045 hasConceptScore W4313642045C535046627 @default.
- W4313642045 hasConceptScore W4313642045C61511704 @default.
- W4313642045 hasConceptScore W4313642045C61943457 @default.
- W4313642045 hasConceptScore W4313642045C71924100 @default.
- W4313642045 hasIssue "23" @default.
- W4313642045 hasLocation W43136420451 @default.
- W4313642045 hasOpenAccess W4313642045 @default.
- W4313642045 hasPrimaryLocation W43136420451 @default.
- W4313642045 hasRelatedWork W1966640052 @default.
- W4313642045 hasRelatedWork W2064879719 @default.
- W4313642045 hasRelatedWork W2068377708 @default.
- W4313642045 hasRelatedWork W2085830368 @default.
- W4313642045 hasRelatedWork W2275480158 @default.
- W4313642045 hasRelatedWork W2324954285 @default.
- W4313642045 hasRelatedWork W2904786998 @default.
- W4313642045 hasRelatedWork W3095306390 @default.
- W4313642045 hasRelatedWork W4223631261 @default.
- W4313642045 hasRelatedWork W4238089809 @default.
- W4313642045 hasVolume "99" @default.
- W4313642045 isParatext "false" @default.
- W4313642045 isRetracted "false" @default.
- W4313642045 workType "article" @default.